United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $483.28, for a total value of $1,933,120.00. Following the completion of the transaction, the chief executive officer directly owned 130 shares in the company, valued at $62,826.40. This represents a 96.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
United Therapeutics Trading Down 2.0%
UTHR stock opened at $479.51 on Tuesday. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $492.62. The firm has a 50-day moving average of $454.01 and a two-hundred day moving average of $369.93. The firm has a market capitalization of $20.65 billion, a PE ratio of 18.17, a P/E/G ratio of 4.86 and a beta of 0.86.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. The business had revenue of $799.50 million for the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm's quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the firm posted $6.39 earnings per share. On average, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 earnings per share for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Chung Wu Investment Group LLC acquired a new stake in United Therapeutics in the second quarter valued at approximately $29,000. WealthCollab LLC lifted its stake in shares of United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock worth $30,000 after purchasing an additional 46 shares in the last quarter. SVB Wealth LLC bought a new stake in United Therapeutics in the first quarter worth $32,000. Finally, Wilmington Savings Fund Society FSB increased its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company's stock worth $37,000 after buying an additional 49 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
UTHR has been the topic of several recent analyst reports. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Royal Bank Of Canada upped their price target on United Therapeutics from $569.00 to $587.00 and gave the company an "outperform" rating in a research report on Thursday, October 30th. Oppenheimer raised their price objective on United Therapeutics from $510.00 to $575.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of United Therapeutics in a research note on Monday, December 1st. Finally, HC Wainwright increased their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a "buy" rating in a research report on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $505.00.
Get Our Latest Stock Analysis on United Therapeutics
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
